Table 2.
IC50 of monotherapy and combinations and their CI – additive (CI = 1), synergistic (CI < 1) or antagonistic effect (CI > 1).
| Monotherapy | RD 18 | A204 | TC71 | |||
|---|---|---|---|---|---|---|
| IC50 (uM) | ||||||
| Sorafenib | 5 | 5 | 5 | |||
| 17‐DMAG | 10 | 10 | 3 | |||
| Abacavir | Not reached | 750 | 375 | |||
| Vorinostat | 3 | 1 | 2 | |||
| Combination | IC50 (uM) | CI | IC50 (uM) | CI | IC50 (uM) | CI |
| Sorafenib | 2.5 | 0.8 | 2.5 | 0.7 | 2.5 | 0.5 |
| 17‐DMAG | 5 | 10 | 5 | |||
| Sorafenib | 2.5 | 1.1 | 5 | 1.4 | 2.5 | 1.1 |
| Abacavir | 375 | 188 | 188 | |||
| Sorafenib | 5 | 0.7 | 5 | 0.9 | 2.5 | 0.8 |
| Vorinostat | 1.5 | 3 | 3 | |||
| 17‐DMAG | 10 | 1.1 | 5 | 1.2 | 5 | 1 |
| Abacavir | 188 | 750 | 188 | |||
| 17‐DMAG | 1.5 | 3 | 1.5 | 0.7 | 1.5 | 0.6 |
| Vorinostat | 0.75 | 3 | 0.75 | |||
| Abacavir | 750 | 1.9 | 750 | 3.7 | 188 | 1.4 |
| Vorinostat | 3 | 3 | 3 | |||